Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Characterization of MicroRNA Expression Levels and Their Biological Correlates in Human Cancer Cell Lines
2007 StandoutNobel
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
2007 Standout
Identification of a Chemical Inhibitor of the Oncogenic Transcription Factor Forkhead Box M1
2006
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Breast cancer
2019 Standout
Basal cell carcinomas: attack of the hedgehog
2008 Standout
Head and neck squamous cell carcinoma
2020 Standout
Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay
2006
The Role of Short-Chain Fatty Acids in Health and Disease
2014 Standout
Lung cancer epigenetics: From knowledge to applications
2017
The third dimension bridges the gap between cell culture and live tissue
2007 Standout
Cellular senescence: when bad things happen to good cells
2007 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Wnt signaling in cancer
2016 Standout
TGF-β: the master regulator of fibrosis
2016 Standout
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
2006
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Polymer conjugates: nanosized medicines for treating cancer
2005
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study
2011
Blocking the Class I Histone Deacetylase Ameliorates Renal Fibrosis and Inhibits Renal Fibroblast Activation via Modulating TGF-Beta and EGFR Signaling
2013
Cancer stem cells revisited
2017 Standout
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
The Epigenomics of Cancer
2007 Standout
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Autophagy: Renovation of Cells and Tissues
2011 Standout
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
2006 Standout
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
2010
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small‐molecule screening and structural databases
2005
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Novel patterns of response under immunotherapy
2019
Pyroptosis: mechanisms and diseases
2021 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Aberrant Wnt/β-Catenin Signaling in Pancreatic Adenocarcinoma
2006
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
The head and neck cancer immune landscape and its immunotherapeutic implications
2016
Ultrafine Hydrogel Nanoparticles: Synthetic Approach and Therapeutic Application in Living Cells
2007
Designing hydrogels for controlled drug delivery
2016 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005 Standout
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
2003
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
2019
Challenges and opportunities in childhood cancer drug development
2012
Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase
2004
Gut microbiota, metabolites and host immunity
2016 Standout
Defining the Role of mTOR in Cancer
2007 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells
2009
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
2013 StandoutNature
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
2005 Standout
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Success in translational research: lessons from the development of bortezomib
2006
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas
2004
Magnesium in Man: Implications for Health and Disease
2014 Standout
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma
2006
New and emerging HDAC inhibitors for cancer treatment
2014
Protein Kinase Inhibitors: Insights into Drug Design from Structure
2004 Science
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
2013
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
2011
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
2007
Therapeutic potential of phosphoinositide 3-kinase inhibitors
2004
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
2006
Transcriptional control of human p53-regulated genes
2008 Standout
Evolution of CASK into a Mg 2+ -Sensitive Kinase
2010 StandoutNobel
Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer
2022 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Histone Deacetylase Inhibitors: From Bench to Clinic
2008
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition
2014 Standout
Ultrafine Hydrogel Nanoparticles: Synthetic Approach and Therapeutic Application in Living Cells
2007
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
2016
Histone Deacetylase Inhibitors in Cancer Therapy
2009
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
2012
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies
2007
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Synthesis and Histone Deacetylase Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold
2009
The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model
2004
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor
2004
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
2010
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
2020 StandoutNobel
Works of Manish Monga being referenced
Developmental Therapeutics Program at the NCI: molecular target and drug discovery process
2002
Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes
2017
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma
2005
Signal Transduction–Directed Cancer Treatments
2003
Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.
2016